Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity

Magnetic resonance is a key imaging tool for the detection of prostate cancer; however, better tools focusing on cancer specificity are required to distinguish benign from cancerous regions. We found higher expression of claudin-3 (CLDN-3) and -4 (CLDN-4) in higher grade than lower-grade human prostate cancer biopsies (n = 174), leading to the design of functionalized nanoparticles (NPs) with a non-toxic truncated version of the natural ligand Clostridium perfringens enterotoxin (C-CPE) that has a strong binding affinity to Cldn-3 and Cldn-4 receptors. We developed a first-of-its-type, C-CPE-NP-based MRI detection tool in a prostate tumor-bearing mouse model. NPs with an average diameter of 152.9 +/- 15.7 nm (RS1) had a 2-fold enhancement of tumor specificity compared to larger (421.2 +/- 33.8 nm) NPs (RS4). There was a 1.8-fold (P < 0.01) and 1.6-fold (P < 0.01) upregulation of the tumor-to-liver signal intensities of C-RS1 and C-RS4 (functionalized NPs) compared to controls, respectively. Also, tumor specificity was 3.1-fold higher (P < 0.001) when comparing C-RS1 to C-RS4. This detection tool improved tumor localization of contrast-enhanced MRI, supporting potential clinical applicability. (c) 2021 Elsevier Inc. All rights reserved.

Automated summary

Magnetic resonance is a key imaging tool for detecting prostate cancer, but more cancer-specific tools are needed to distinguish benign from cancerous regions. Higher expression of CLDN-3 and CLDN-4 was found in higher-grade prostate cancer, leading to the development of functionalized nanoparticles with a strong binding affinity to these receptors. The use of these nanoparticles improved tumor specificity in a prostate tumor-bearing mouse model, demonstrating potential clinical applicability.